ENANTA PHARMACEUTICALS, INC Available-for-sale Securities, Amortized Cost Basis
ENANTA PHARMACEUTICALS, INC (ENTA) had Available-for-sale Securities, Amortized Cost Basis of $223.08 million as of 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-10
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $223.08M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $230.07M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $228.21M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $213.29M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $223.08M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $230.07M 10-Q · filed 2018-02-09 |
| 2017-09-30 | $228.21M 10-Q · filed 2018-05-10 |
| 2017-06-30 | $213.29M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $221.87M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $223.91M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $225.60M 10-K · filed 2017-12-11 |
| 2016-06-30 | $219.68M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $189.20M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $190.71M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $187.66M 10-K · filed 2016-12-09 |
| 2015-06-30 | $192.16M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $201.01M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $93.55M 10-Q · filed 2015-02-06 |
| 2014-09-30 | $101.17M 10-K · filed 2015-12-11 |
| 2014-06-30 | $111.22M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $83.79M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $101.70M 10-Q · filed 2014-02-13 |
| 2013-09-30 | $103.33M 10-K · filed 2014-12-11 |
| 2013-06-30 | $95.98M 10-Q · filed 2013-08-12 |
| 2013-03-31 | $47.28M 10-Q · filed 2013-05-15 |
| 2012-09-30 | $34.90M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |